5-[5-[2-(3,5bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists

Details for Australian Patent Application No. 2009248102 (hide)

International Classifications

Event Publications

2 December 2010 PCT application entered the National Phase

PCT publication WO2009/138393 Priority application(s): WO2009/138393

28 June 2012 Application Accepted

Published as AU-B-2009248102

26 July 2012 Corrigenda

Applications Accepted - Name Index Under the name Glaxo Wellcome Manufacturing Pte Ltd, Application No. 2009248102, under INID (54) correct the title to read 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylCorrigenda amino]-4- (4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists

25 October 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.